International Journal of Cancer · 2001 · 36 citations · 11 references
MedicineOncologyRadiation OncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCombination ImmunotherapyExternal Beam DosimetryExternal Beam RadiotherapyRadiation TherapyAnti-cd20 Antibody TherapyAnti-cd20 TherapyImmune Modulation By RadiationRadiation Therapy CombinationsRadiation-enhanced ImmunotherapyRadiotherapy CombinationsRadiotherapy-induced Immunogenic Cell DeathTumor Targeting Specificity
The CD20 surface antigen is expressed on the great majority of B-cell lymphoma cases. The expression of this antigen ranges from moderate to bright, and it is neither internalized nor shed. These characteristics make CD20 a common target for antibody directed lymphoma therapy. The development of strategies to significantly increase CD20 expression on lymphoma cells is therefore of great interest as a means of increasing specific targeting and cell kill in antibody therapy and radio-immunotherapy. We present here data demonstrating that relatively low doses of external beam radiotherapy are capable of significant and consistent increases in CD20 surface expression in vitro. The effect is dose related up to approximately 10 Gy and is maximal in the first day after radiotherapy. We believe that these data may suggest a potent way to combine a short pretreatment course of external beam radiotherapy with a subsequent course of immunotherapy using either an unlabeled antibody or a radio-immunotoxin.
11
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text
Life Sciences, Immunology, Pathology +14
Recent Cancer Trends in the United States
Susan S. Devesa, W. J. Blot, B. J. Stone et al. · JNCI Journal of the National Cancer Institute · 1995 · 423 citations
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Frederick R. Appelbaum, JA Ledbetter, Martin Pj et al. · Blood · 1987 · 354 citations · Full text
Medicine, Hematology, Oncology +14
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Oliver W. Press, Andrew G. Farr, K.I. Borroz et al. · PubMed · 1989 · 252 citations
Life Sciences, Immunology, Oncology +17